绂忓缓蹇笁浠婃棩寮€濂? Successful start to fiscal year 2019/20 for Carl Zeiss Meditec with profitable growth

Both strategic business units achieve double-digit percentage increases in revenue

Jena/Germany | 10 February 2020 | Carl Zeiss Meditec AG

Carl Zeiss Meditec generated revenue of €369.7m in the first three months of fiscal year 2019/20, which corresponds to an increase of 14.2% (adjusted for currency effects: +12.7%) compared with the prior-year period (prior year: €323.6m). Both strategic business units achieved significant increases in revenue. Earnings before interest and taxes (EBIT) rose as a result of the increase in revenue, to €56.8m (prior year: €48.1m). The EBIT margin increased further, to 15.4% (prior year: 14.9%).

“We have made a successful start to the new fiscal year and can report encouraging growth in all business segments. Both our traditional equipment business and our consumables business made outstanding contributions to this,” says Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG.

Double-digit growth in both strategic business units

The strategic business unit (SBU) Ophthalmic Devices increased its revenue by 12.5 percent after the first three months of fiscal year 2019/20 (adjusted for currency effects: +11.1 percent), to €269.4m (prior year: €239.5m). Revenue in the Microsurgery SBU grew by 19.1 percent (adjusted for currency effects: +17.4 percent), to €100.3m (prior year: €84.2m).

Balanced growth in all business regions

Revenue in the EMEA region grew by 7.0 percent (adjusted for currency effects: +6.9 percent), to €110.7m (prior year: €103.5m). The core markets Germany and France achieved good revenue growth.

The Americas region increased its revenue by 18.5 percent after the first three months of the current fiscal year (adjusted for currency effects: 15.5 percent), to €109.0m (prior year: €91.9m). High contributions to growth came from the USA, as well as positive impetus from Latin America.

The APAC region also achieved further growth of 16.9 percent (adjusted for currency effects: +15.5 percent), to €150.0m (prior year: €128.2m). Countries such as China and South Korea once again made the strongest contributions to growth. The Japanese market also recorded good demand.

The operating result (earnings before interest and taxes: EBIT) increased significantly in the first quarter of fiscal year 2019/20, reaching €56.8m (prior year: €48.1m). The EBIT margin increased from 14.9 percent to 15.4 percent. Adjusted for special effects, this resulted in an increase to 15.7 percent (prior year: 15.1%). Earnings per share rose to €0.43 (prior year: €0.32).

“In fiscal year 2019/20, we anticipate revenue growth that is at least in line with our markets. In terms of the development of earnings, we expect to achieve an EBIT margin of between 17% and 19% in the current fiscal year” says Dr. Monz, confirming the outlook published in December 2019.

Revenue by strategic business unit

All figures in €m

3 months
2019/20

3 months
2018/19

Change from
prior year?

Change from
prior year*

Ophthalmic Devices

269.4

239.5

+12.5%

+11.1%

Microsurgery

100.3

84.2

+19.1%

+17.4%

Overall group

369.7

323.6

+14.2%

+12.7%

*adjusted for currency effects

Revenue by region

All figures in €m

3 months
2019/20

3 months
2018/19

Change from
prior year?

Change from
prior year*

EMEA

110.7

103.5

+7.0%

+6.9%

Americas

109.0

91.9

+18.5%

+15.5%

APAC

150.0

128.2

+16.9%

+15.5%

Overall group

369.7

323.6

+14.2%

+12.7%

*adjusted for currency effects

Press Contact

Sebastian Frericks
Director Investor Relations
Carl Zeiss Meditec AG
Phone: +49 3641 220-116
investors .meditec @zeiss .com

Brief Profile

Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world’s leading medical technology companies.?The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With 3,232 employees (as of 30 September 2019) worldwide, the Group generated revenue of €1,459.3m in fiscal year 2018/19 (as of 30 September).

The Group’s head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 41 percent of Carl Zeiss Meditec AG’s shares are in free float. The remaining approx. 59 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries.

For more information visit our website at www.zeiss.com/med

Press Contact

Sebastian Frericks
Director Investor Relations
Carl Zeiss Meditec AG
Phone: +49 3641 220-116
investors .meditec @zeiss .com

Further Information
Share
Further Articles